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Abstract 
Objectives: Individual variability in the response to aspirin, has been established by various platelet function assays, 
however, the clinical relevance of aspirin resistance (AR) in patients undergoing coronary artery bypass grafting 
(CABG) has to be evaluated.  
Methods: Our working group conducted a randomized controlled trial (NCT01159639) with the aim to assess impact 
of dual antiplatelet therapy (APT) on outcomes among patients with AR following CABG. Patients that were aspirin 
resistant on fourth postoperative day (POD 4) were randomly assigned to receive either dual APT with clopidogrel 
(75mg) plus aspirin (300mg) – intervention arm or monotherapy with aspirin (300mg) – control arm. This exploratory 
analysis compares clinical outcomes between aspirin resistant patients allocated to control arm and patients that have 
had adequate platelet inhibitory response to aspirin at POD 4. Both groups were treated with 300 mg of aspirin per 
day following surgery. We sought to evaluate the impact of early postoperative AR on outcomes among patients 
following CABG. 
Results: Exploratory analysis included a total number of 325 patients. Of those, 215 patients with adequate response 
to aspirin and 110 patients with AR allocated to aspirin monotherapy following randomization protocol. The primary 
efficacy end point (MACCEs - major adverse cardiac and cardiovascular events) occurred in 10% and 6% of patients 
with AR and with adequate aspirin response, respectively (p=0.27). Non-significant differences were observed in 
bleeding events occurrence. Subgroup analysis of the primary end point revealed that aspirin resistant patients with 
BMI > 30 kg/m
2
 tend to have a higher occurrence of MACCEs 18% vs. 5% (relative risk 0.44 [95% CI 0.16-1.16]; 
p=0.05). 
Conclusions: This exploratory analysis did not reveal significant impact of aspirin resistance on outcomes among 
patients undergoing CABG. Further, sufficiently powered studies are needed in order to evaluate clinical relevance of 
AR in patients undergoing CABG.   
Keywords: Aspirin resistance; Multiple electrode aggregometry; Platelet aggregation inhibitors; Coronary artery 
bypass surgery; platelet function 
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Introduction  
Clinical outcomes in coronary artery bypass grafting (CABG) surgery depend mainly on the patency of the graft 
vessels. Three distinct but interrelated pathological processes such as thrombosis, intimal hyperplasia and 
atherosclerosis
1
 contribute to graft failure following CABG
1
. Early thrombosis is a major cause of graft failure during 
the first month after CABG
1, 2
. Beneficial effect of antiplatelet therapy (APT) in early postoperative phase is therefore 
important and has been reported in literature
3-5
. Aspirin is the most commonly prescribed antiplatelet drug following 
CABG
6
. When postoperatively administered, aspirin is associated with a 40% reduction in bypass graft occlusions 
occurence
6, 7
.  Current guidelines on APT administration following CABG recommend initiation of 100 to 325 mg of 
aspirin starting within 6 hours of surgery
8, 9
. However, not all patients respond equally to APT, thus continuous 
refinement in postoperative APT management is warranted. Current guidelines
8
 recommend the one-size fits-all 
strategy in administration of APT postoperatively, which certainly disregards wide variability in platelet inhibitory 
response to APT
8
. Even though there is no consensual definition of aspirin resistance (AR), literature reveals that up 
to 83.3% of patients inadequately respond to this drug based on in vitro platelet function testing
10
. Despite existing 
huge variability in platelet inhibitory response to aspirin, wide range in percentage of aspirin resistance prevalence 
dominantly stems in a lack of methodological consensus to define AR as well as in numeruous different tests available 
to quantify platelet function. Notably, the degree of agreement between the various assays to quantify platelet 
inhibitory response to aspirin is poor
10
. Clinical causes as well as pathophysiological mechanisms for AR onset are 
numerous. In addition to interindividual differences in platelet inhibitory response to aspirin, it is very important to 
stress out that antiplatelet effect of aspirin may vary intraindividually
11-13
. This is of particular relevance in patients 
undergoing CABG, as there is evidence that cardiopulmonary bypass contributes to hyperactivity onset in 
postoperative phase
2, 12, 14, 15
. Although there is evidence on AR prevalence in patients undergoing CABG, the clinical 
impact of AR on outcomes among patients following CABG remains elusive. The level of clinical relevance to which 
the term “aspirin resistance” may be attached remains unclear. The concept of AR has been debated since the 1980s16 
and the more recent literature evaluates the level of clinical relevance that may be attached to the term “aspirin 
resistance”16. 
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Also it remains challenging to optimize postoperative APT management because individual variability in platelet 
inhibitory response to APT varies widely and is unpredictable. The aim of this exploratory analysis from the 
randomized trial (NCT01159639) was to evaluate the impact of AR presence detected with multiple electrode 
aggregometry (MEA) in early postoperative phase on outcomes among patients following CABG.  
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Materials and methods 
Design of randomized controlled trial (NCT01159639) 
NCT01159639 randomized controlled trial was a single-center randomized controlled trial that evaluated the addition 
of clopidogrel to aspirin on outcomes among patients found to have AR early postoperatively. Institutional review 
board approved the study and written informed consent was obtained for each patient considered for inclusion in the 
randomized controlled study. We adhered to ethical standards in line with the Declaration of Helsinki. Study design 
details and eligibility criteria have previously been published
17
. In brief, 2034 patients were initially assessed for 
eligibility and 439 patients underwent platelet function testing on the fourth postoperative day (POD 4). 224 out of 
439 patients were found to be aspirin resistant at POD 4 and were randomly assigned to receive clopidogrel (75mg) 
plus aspirin (300mg) – interventional arm or aspirin-monotherapy (300mg) – non-interventional (control) arm17. 
Patients having adequate platelet inhibitory response to aspirin at POD 4 were initially excluded from the randomized 
controlled trial. These patients were included in the follow up as this exploratory analysis has been prospectively 
designed.  
Patient selection  
Study flowchart for this exploratory analysis is shown in Figure 1. A total number of 439 patients finally underwent 
platelet function testing at POD 4. Of those, 215 have had adequate platelet inhibitory response to aspirin therapy 
(aspirin responders) and continued to receive aspirin 300 mg/day postoperatively. Of 224 aspirin resistant patients that 
were randomized, 110 were allocated to aspirin monotherapy (control group) and continued to receive aspirin 300 
mg/day postoperatively. 185 aspirin responders and 107 aspirin resistant patients allocated to aspirin monotherapy 
were finally included in the intention-to-treat analysis and were compared to each other with aim to evaluate clinical 
relevance of the AR among patients following CABG who continued to receive aspirin 300 mg/day monotherapy 
postoperatively.  
Perioperative management 
All patients had the same anesthetic and perfusion teams and were admitted at least 1 day before surgery. Surgery was 
performed in a single unit with standard surgical techniques. The critical components of the employed 
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cardiopulmonary circuit were the Medtronic Affinity Trillium membrane oxygenator, venous reservoir, PVC tubing 
(Medtronic, Minneapolis, MN, USA), and a Stoeckert III roller pump (Stoeckert, Munich, Germany). The ascending 
aorta and right atrium were cannulated for CPB. Myocardial protection consisted of both antegrade and retrograde 
cold blood cardioplegia. Systemic heparinization aiming at an activated clotting time >480 s was used, followed by 
full reversal with protamine after decannulation. A dose of 1 g tranexamic acid was given at the induction of 
anesthesia and after protamine administration. Distal coronary anastomoses were performed on an arrested heart 
during a single period of aortic cross-clamping. Weaning from CPB was initiated once the patient’s rhythm had 
stabilized and normothermia had been achieved. Inotropic support was initiated in order to maintain a cardiac index 
greater than 2.2 l/min/m
2
.  
Blood sampling 
Blood samples were obtained at POD 4 using venipuncture, and 4 ml blood was collected in 4 ml heparin (Lithium 
Heparin 68 IU) coated BD Vacutainer plastic tubes.  
Multiple-electrode aggregometry (MEA) 
Whole blood platelet aggregation was determined using MEA (Multiplate
®
, Verum Diagnostica GmbH and Dynabyte 
Informationssysteme GmbH, Munich, Germany)
18
. Increase in impedance is expressed in arbitrary area under the 
curve (AUC) units, highlighted as the parameter with the highest diagnostic power
18
 . The samples were incubated for 
3 min and platelet aggregation was measured 6 min after stimulation. Platelet aggregation was determined in response 
to stimulation with arachidonic acid with a final concentration of 0.5 mM (ASPI test designed to evaluate aspirin 
effect) and adenosine diphosphate (ADP) with a final concentration of 6.4 µM (ADP test designed to evaluate 
thienopyridines, such as clopidogrel, effect). The same person, not directly involved in patient care, performed all the 
measurements. Individuals processing the samples as well as individuals collecting follow up data were unaware of 
treatment group.  
Primary and secondary outcome  
More in detail data regarding primary and secondary outcomes have been already published
17,19
. Put briefly, the 
primary efficacy end point was the incidence of major adverse cardiac and cerebrovascular events (MACCEs) after 6 
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months follow up
19
. MACCE has been defined as a composite end point consisted of all-cause mortality, nonfatal 
myocardial infarction (MI), cerebrovascular accident, and cardiovascular rehospotalization. Individual MACCE 
components, as well as bleeding events characterized according to Bleeding Academic Research Consortium (BARC) 
definitions
20
 (safety end point data) were considered as the secondary outcomes. 
Statistical analysis 
The continuous data were presented as mean values with their standard deviation. Categorical variables were 
presented as absolute numbers with percentages. A value of p≤0.05 was considered statistically significant. The 
Mann-Whitney U test was used to analyze continuous data between the two groups. Comparison between the 
categorical variables was performed with Fisher’s exact test. Relative risks (RR) were used as a measure of the 
association between the response to aspirin and clinical outcomes. The respective 95% confidence intervals (CI) were 
provided. Changes in the platelet reactivity in response to surgery were evaluated with the Wilcoxon matched-pairs 
test. The data were processed using the IBM SPSS Statistics software package (version 20.0; Somers, New York)
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Results 
Baseline demographic and operative data 
Baseline demographic and clinical profiles of the two compared groups are shown in Table 1. Significant differences 
were observed between the two groups in respect to age, body mass index, left main disease and angiotensin-
converting enzyme inhibitor preoperative administration. We believe that those differences did not influence the 
clinical outcomes. Although age is one of the strongest predictors of adverse events, the fact is that 2 year difference 
may be of questionable significance. In addition to, EuroSCORE scoring system that accounts for age was not 
significantly different between groups. No differences were observed in perioperative details such as left internal 
mammary use, cross-clamp time (min), cardiopulmonary bypass time (CPB) and perioperative inotrope use (Table 2.). 
Platelet function testing results  
We observed significant differences in preoperative platelet aggregability between the groups (Table 1.). Aspirin 
resistant patients allocated to Aspirin monotherapy “control” arm have had higher value of ASPI test (38±28 vs. 
23±20 AUC, p<0.001). The similar findings were found for the ADP test (80±25 vs. 68±28 AUC, p<0.001). The same 
trend of higher ASPI and ADP test values in aspirin resistant patients allocated to aspirin monotherapy comparing to 
aspirin responders was noted postoperatively (Table 2.). Of more importance, we observed significant difference in 
platelet reactivity turnover in response to surgery (Figure 2.). In aspirin resistant patients allocated to aspirin 
monotherapy we observed statistically significant increase of platelet aggregability in response to surgery for both the 
ASPI (38±28 vs. 53±22 AUC, p<0.001) and ADP (80±25 vs. 97±31 AUC, p<0.001) tests. Aspirin responders 
expressed a similar phenomenon for ADP test (68±28 vs 84±36 AUC, p<0.001). However, in aspirin responders 
group, there was no platelet aggregability increase in response to surgery for the ASPI test (23±20 vs. 20±6, p = 
0.857). Hence, it seems that patients with adequate platelet inhibitory response to aspirin did not experience platelet 
reactivity turnover in response to surgery.   
Clinical outcomes 
Two groups were analyzed for differences in the primary and secondary study outcomes (Table 3.). The primary 
efficacy end point (MACCEs - major adverse cardiac and cardiovascular events) occurred in 10% and 6% in patients 
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with AR and with adequate aspirin response, respectively (p=0.27). All-cause death (4 vs. 2%), stroke (4 vs. 1%) and 
composite MI or stroke or cardiovascular death (3 vs. 2%) occurred more frequently in Aspirin resistant patients, 
however, those differences did not reach statistical significance. Non-significant differences were observed in 
bleeding events occurrence (Table 3.). Subgroup analysis of the primary end point (Table 4.) revealed that aspirin 
resistant patients with BMI > 30 kg/m2 tend to have a significantly higher occurrence of MACCEs 18% vs. 5% (RR 
0.44 [95% CI (0.16-1.16); p=0.05).  
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Discussion 
In this exploratory analysis of prospectively collected data within randomized controlled trial (NCT01159639) 
we sought to evaluate the impact of AR, detected by MEA, on clinical outcomes during the 6 month follow up period 
after CABG. Concerning efficacy end points, we observed that adverse events such as MACCEs (10 vs. 6%), all-
cause death (4 vs. 2%), stroke (4 vs. 1%) as well as composite MI or stroke or cardiovasvular death (5 vs. 2%), 
occurred more frequently in patients with AR, however statistical significance has not been reached. Subgroup 
analysis of the primary end point revealed that AR may significantly affect clinical outcomes in patients with BMI > 
30 kg/m
2
 (Table 4.). Non-significant differences were observed in bleeding events occurrence. Considering the 
bleeding outcomes, previously we have conducted studies where the pronounced preoperative platelet inhibition 
reflected on the amount of early postoperative bleeding
21, 22
.  In contrast to short term bleeding outcomes that 
correlated well with platelet function
21-23
, we have found non-significant differences between aspirin sensitive and 
aspirin resistant patients in terms of bleeding outcomes, defined according to BARC
20
 criteria and evaluated after six 
months of follow up. We found that 51% of patients undergoing isolated CABG were aspirin resistant in early 
postoperative phase
19
. These results are in line with those previously published by our working group
2
 where we 
found that 46.5% of patients were aspirin resistant at POD 4
2
. Postoperatively registered increase of 15.2% in the 
proportion of patients with AR was found to be significant
2
. Very similar phenomenon was observed at the 
randomized controlled trial study cohort
19
. However, this exploratory analysis comparing aspirin resistant patients and 
patients with adequate platelet inhibitory response showed markedly different results
19
. In contrast to aspirin resistant 
patients where we observed significant increase of platelet aggregability in response to surgery (ASPI test, 38±28 vs. 
53±22 AUC, p<0.001), in aspirin responders group, there was no platelet reactivity turnover in response to surgery for 
the ASPI test (23±20 vs. 20±6, p = 0.857). Hence, it seems that patients having adequate platelet inhibitory response 
to aspirin did not experience platelet hyperactivity turnover in response to surgery.  
Extensive evidece describing the phenomenon of AR in patients undergoing cardiac surgery is available in 
literature
11, 24, 25
. Based on underlying mechanisms, we can assume that there are three types of aspirin resistance: 
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1) Pharmacokinetic AR where inadequate in vivo efficacy exists despite sufficient in vitro performance
24, 25
. In 
such a cases, patient non-compliance, inadequate absorption and drug to drug interactions should be 
considered
24, 25
. 
2) Pharmacodynamic AR may be considered in cases where is incomplete (cyclooxygenase-1) COX-1 inhibition 
presented in spite adequate plasma concentration
12
.  Early postoperative increased platelet turnover and 
reactivity
12
 as well as COX-1 polymorphism may be underlying cause for such a phenomenon
24, 25
. 
3) Pseudoresistance implies that adequate COX-1 inhibition is achieved, however platelet express activation via 
thromboxane independent pathways
24, 25
. This type of AR underlines the importance of comprehensive 
approach in management of AR. Drugs affecting other pathways of platelet activation should be considered in 
such cases. Not only aspirin resistant, but also patients with adequate platelet inhibitory response to aspirin 
may express at the same time platelet adenosine di-phosphate (ADP) receptor hyperactivity. In such a 
subgroup of patients with hyperactive ADP platelet receptors, thienopyridines should be considered. 
Moreover, platelet ADP receptor inhibitory response to thienopyridines should be quantified, as there is 
evidence that up to 30% of patients on clopidogrel may be considered as clopidogrel resistant
24, 26
. 
Optimal postoperative APT management certainly requires comprehensive approach. Assessment of platelet 
inhibitory response to aspirin therapy is representative of only one pathway of platelet reactivity. Therefore, it is 
difficult to expect that achievement of adequate platelet inhibition in only one platelet activation pathway may 
efficiently prevent adverse ischemic events in patients with CABG being performed. Significant number of patients 
treated with aspirin has major adverse, vascular related events every year
27
. Contrary to patients who benefit from 
aspirin therapy, patients that experience adverse ischemic events while on aspirin therapy may be labeled as “aspirin 
resistant”. Platelets of aspirin resistant patients generally do not achieve adequate platelet inhibitory response to 
aspirin. Notably, recent evidence suggests that clopidogrel improves aspirin response and dual antiplatelet therapy 
(aspirin plus clopidogrel) results with significantly lower incidence of AR comparing to aspirin monotherapy
28
.  In 
patients labeled as aspirin resistant, aspirin dose increase or addition of other antiplatelet drug could be considered as 
a measure to overcome residual platelet reactivity. The Bochum CLopidogrel and Aspirin Plan (BOCLA-Plan)
29
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incorporating a “test and treat” strategy effectively eliminated AR by dose modification after subsequent platelet 
function testing being performed
29
. Notably, when considering increase of aspirin dosage up to 500 mg/day, it is 
important to understand that high-dose of aspirin may worsen endothelial mediated arterial dilatation
30
. In patients 
following CABG, the possible impact of each antiplatelet agent administered postoperatively should separately be 
assessed by drug specific platelet function testing
31
 . Such an approach could distinguish patients with high residual 
on-treatment platelet reactivity, thus proclivity to ischemic events, from those with pronounced platelet inhibition, 
who are prone to bleeding events
31
. Personalized approach directed after drug specific platelet function test results 
could be considered in postoperative APT management
31
. Furthermore, platelet function testing could be performed 
repetitively in certain timeframes
31
. Recently, our working group performed randomized controlled trial with aim to 
evaluate the effect of serial clopidogrel dose adjustment based on MEA results on clinical outcomes of patients 
undergoing percutaneous coronary intervention
32
. Study showed that clopidogrel dose adjustment according to MEA 
results have led to better platelet inhibition in patients with initial high residual platelet reactivity. In addition,  
patients in the interventional group (drug dose adjustment targeted after MEA results) had a significantly better 
outcome and survival to an adverse event (ischemic or bleeding)
32
. Considering variability in platelet reactivity 
through time, we assume that longitudinal follow up based on repetitive MEA testing could target the therapeutic 
window of platelet reactivity which in turn could help to minimize both bleeding and ischemic events in patients 
following CABG. However, prospective randomized trials are needed to confirm this hypothesis.  
 
Review of literature 
There is shortage of literature evaluating the relation of AR and its impact on clinical outcomes following CABG. 
Gluckman et al evaluated effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after 
CABG
33
. Thromboxane generation (increased levels of urinary 11-dehydro thromboxane B2) and shear-dependent 
platelet hyper-reactivity were independent risk factors for early saphenous vein graft thrombosis after CABG
33
. 
Investigator in the prevention of Coronary Artery Bypass Occlusion After CABG (CRYSSA trial) reported an 
alarming correlation between resistance to APT and graft occlusion (RR, 3.6; 95% CI, 2.5-6.9; p<0.001)
34
. Review 
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and meta-analysis published by Snoep et al
35
 have shown that aspirin resistant patients are at increased risk of 
recurrent cardiovascular events compared with aspirin sensitive patients
35
. Similarly to Snoep et al
35
, Krasopoulos et 
al
16
 evaluated relation between AR and clinical outcomes in patients with cardiovascular disease
16
. Using systematic 
search, authors identified 20 studies, totaling 2930 patients
16
. Of those, 2120 were classified as aspirin sensitive and 
the remaining 810 (28%) as aspirin resistant
16
. These results
16
 are in line with those published by our working group
2
. 
In prospective observational study evaluating perioperative changes in platelet reactivity in patients undergoing 
CABG
2
, we have found that 31.3% of patients undergoing CABG were aspirin resistant preoperatively
2
. Therefore, 
one may expect that approximately one third of patients treated with aspirin may be aspirin resistant.  Krasopoulos et 
al
16
 have found that aspirin resistant patients were at greater risk of clinically important adverse cardiovascular 
events
16
. The odds ratio for increased mortality in aspirin resistant patients was 5.99 (2.28 to 15.72; p<0.003)
16
. 
Similarly to our findings from randomized controlled trial
19
, authors reported
16
 that concomitant therapy with other 
antiplatelet agent provided no benefit to those patients labeled as aspirin resistant
16
. 
Study limitations and methodological considerations 
As we discussed ealier
19
, we cannot exclude the possibility that the study may have been underpowered
19
 despite the 
fact we performed initially sample size calculation based on exact binomial test power analysis
17, 19
. Further, similar 
designed, multicentric studies that would be sufficiently powered to assess the impact of AR on clinical outcomes. 
Furthermore, our trial has not initially been designed to estimate durability of AR, as MEA has been performed solely 
on POD 4 following CABG
17, 19
. In general, we may assume there is permanent as well as transient AR. Patients who 
were found to be aspirin resistant preoperatively are more likely to have permanent AR. In contrast to, patients that 
were aspirin resistant on POD 4, but did have adequate platelet inhibitory response preoperatively, are more likely to 
have temporary/transient AR. In this subgroup of patients it would be interesting to evaluate durability of AR by 
performing repetitively platelet function testing throughout follow up period. In this way it would be possible to 
assess the impact of AR presence as well as longevity of AR on clinical outcomes in patients following CABG. The 
design of randomized controlled study (NCT01159639)
17, 19
 and subsequent exploratory analysis provide data 
insufficient to establish whether patients identified as aspirin resistant on POD 4 remained aspirin resistant or whether 
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patients identified as aspirin sensitive subsequently became aspirin resistant during the follow up period. Further 
studies should inevitably address this drawback by performing subsequently platelet function testing in predefined 
time intervals during the follow up. 
Conclusion 
In order to understand better the relation between AR and clinical outcome, further, sufficiently powered prospective 
multicenter studies are warranted. Adjustment of antiplatelet drug dosage, as well as duration of adjustment regimen 
could be directed according to platelet function test results. Longitudinal follow-up of platelet reactivity might be a 
useful adjunct to standard postoperative APT management protocol aiming to achieve more favorable patient 
outcomes by targeting therapeutic window for each antiplatelet drug being administered
6
. However, such a therapeutic 
approach requires further multicenter randomized controlled trial with a large study cohort that would allow for 
sufficiently powered data analysis and evaluation of such a treatment modality leading to meaningful conclusions.  
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Table 1. 
Table 1. Baseline Demographic and Clinical Profiles (N=294) 
 
 
 
Variable 
Aspirin 
Monotherapy 
(n=107) 
Responders 
(n=185) 
p* 
Age (years) 65±9 63±8 0.03 
Male gender 82 (77%) 146 (79%) 0.66 
Body mass index (kg/m
2
) 30±4 29±4 0.05 
EuroSCORE 3.6±3.7 2.9±2.4 0.17 
LVEF (%) 55±10 55±11 0.90 
Hyperlipidemia
†
 103 (96%) 172 (93%) 0.31 
Diabetes mellitus 41 (38%) 65 (35%) 0.62 
Smoker 41 (38%) 70 (38%) 1.00 
Hypertension
‡
 103 (96%) 178 (96%) 1.00 
Left main narrowing 57 (53%) 67 (36%) 0.01 
Three-vessel coronary disease 80 (75%) 134 (72%) 0.68 
Preoperative platelet reactivity    
ASPI test values, AUC 38±28 23±20 <0.01 
ADP test values, AUC 80±25 68±28 <0.01 
Preoperative medications 
  
 
Clopidogrel 27 (25%) 56 (30%) 0.42 
Aspirin 94 (88%) 172 (93%) 0.14 
B-blocker 83 (78%) 149 (81%) 0.55 
Angiotensin-converting enzyme 
inhibitor 
67 (63%) 159 (86%) <0.01 
Statin 104 (97%) 168 (91%) 0.05 
 
 
* Two-tailed p 
†
 Hyperlipidemia was defined as any of the following: history of hypercholesterolemia (LDL-cholesterol>3.4 mmol/l or total cholesterol>5.2 
mmol/l), hypertriglyceridemia (>1.7 mmol/L), hyperchylomicronemia or use of lipid-lowering medications to achieve target lipid/lipoprotein 
values 
‡ 
Hypertension was defined as 2 or more systolic blood pressure (BP) measurements ≥140 mmHg or diastolic BP readings ≥90 mmHg, or use 
of anti-hypertensive medications to achieve the desired BP values in patients with a history of high BP 
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EuroSCORE=European System for Cardiac Operative Risk Evaluation; LVEF=left ventricular ejection fraction; ASPI=cyclooxygenase 
dependent platelet aggregation; AUC=area under the curve; ADP=adenosine diphosphate 
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Table 2. 
Table 2. Perioperative Details and Postoperative Medication Use 
 
 
 
 
Aspirin 
Monotherapy 
(n=107) 
Responders 
(n=185) 
p* 
Perioperative Data 
  
 
Left internal mammary use 101 (94%) 173 (94%) 1.00 
Cross-clamp time (min) 57±22 55±21 0.35 
CPB time (min) 86±25 82±27 0.16 
Postoperative inotrope use 31 (29%) 51 (28%) 0.79 
Postoperative Platelet Reactivity    
ASPI test values, AUC 53±22 20±6 <0.01 
ADP test values, AUC 97±31 84±36 <0.01 
Postoperative Medications 
  
 
Clopidogrel 0  0 1.00 
Aspirin 107 (100%) 185 (100%) 1.00 
Beta blocker 101 (94%) 178 (96%) 0.56 
Angiotensin-converting enzyme 
inhibitor 
12 (11%) 23 (12%) 0.85 
Statin 100 (93%) 183 (99%) 0.01 
 
 
*Two-tailed p 
CPB=cardiopulmonary bypass; AF=atrial fibrillation; ASPI=cyclooxygenase dependent platelet aggregation; ADP=adenosine diphosphate; 
AUC=area under the curve  
 
22 
 
Table 3. 
Table 3. Primary and Secondary Study Outcomes (Intention-to-Treat Analysis) 
 
 
 
Aspirin 
Monotherapy 
Responders 
Relative Risk 
(95% CI) 
p* 
Efficacy End-points (n=107 ) (n=185)   
MACCE  11 (10%) 12 (6%) 0.81 (0.54-1.21) 0.27 
All-cause death  4 (4%) 4 (2%) 0.79 (0.39-1.58) 0.47 
Cardiovascular death 1 (1%) 2 (1%) 1.05 (0.47-2.36) 1.00 
Stroke  4 (4%) 1 (1%) 0.31 (0.05-1.81) 0.06 
Non-fatal MI  1 (1%) 1 (1%) 0.79 (0.20-3.16) 1.00 
Composite MI or stroke 
or cardiovascular death  
5 (5%) 4 (2%) 0.70 (0.33-1.45) 0.30 
Cardiovascular 
hospitalization 
3 (3%) 6 (3%) 1.05 (0.66-1.69) 1.00 
Safety End-points     
Total bleeding events 20 (19%) 26 (14%) 0.87 (0.67-1.15) 0.32 
BARC 1 19 (18%) 25 (14%) 0.88 (0.67-1.16) 0.40 
BARC 2 0  1 (1%) 1.58 (1.45-1.73) 1.00 
BARC 3 1 (1%) 0 N/A 0.37 
BARC 4 0  0 N/A 1.00 
BARC 5 0  0 N/A 1.00 
 
 
*Two-tailed p 
CI=confidence intervals; MACCE=major adverse cardiac and cerebrovascular events; MI=myocardial infarction; BARC=Bleeding Academic 
Research Consortium 
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Table 4. 
Table 4. Subgroup Analyses of the Primary End-Point 
 
 
 
 
Aspirin 
Monotherapy 
Responders Relative Risk 
(95% CI) 
p* 
Age, y     
≥65 6/58 (10%) 7/82 (9%) 0.91 (0.54-1.54) 0.77 
<65 5/49 (10%) 5/103 (5%) 0.72 (0.39-1.36) 0.29 
Sex     
Male 7/82 (9%) 10/146 (7%) 0.91 (0.61-1.38) 0.79 
Female 4/25 (16%) 2/39 (5%) 0.52 (0.17-1.65) 0.20 
Body mass index, 
kg/m
2
 
    
>30 8/45 (18%) 3/65 (5%)  0.44 (0.16-1.16) 0.05 
≤30 3/62 (5%) 9/120 (8%) 1.15 (0.81-1.62) 0.75 
EuroSCORE     
≥3 6/48 (13%) 7/62 (11%) 0.95 (0.56-1.62) 1.00 
<3 5/59 (8%) 5/123 (4%) 0.73 (0.39-1.37) 0.30 
LVEF     
>50% 5/66 (8%) 5/117 (4%) 0.77 (0.41-1.45) 0.50 
≤50% 6/41 (15%) 7/68 (10%) 0.85 (0.50-1.43) 0.55 
Diabetes mellitus     
Yes 7/41 (17%) 4/65 (6%) 0.57 (0.26-1.26) 0.10 
No 4/66 (6%) 8/120 (7%) 1.04 (0.68-1.57) 1.00 
Three vessel disease     
Yes 8/80 (10%) 10/133 (8%) 0.88 (0.58-1.35) 0.61 
No 3/27 (11%) 2/51 (4%) 0.60 (0.20-1.76) 0.33 
Left main disease     
Yes 8/57 (14%) 3/67 (4%) 0.48 (0.18-1.28) 0.11 
No 3/50 (6%) 9/118 (8%) 1.07 (0.76-1.51) 1.00 
 
 
*Two-tailed p 
CI=confidence interval; EuroSCORE=European System for Cardiac Operative Risk Evaluation; LVEF=left ventricular ejection fraction 
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Figures: 
Figure 1. 
Exploratory analysis flowchart. Patient eligibility, group for analysis selection and follow up. BARC = Bleeding 
Academic Research Consortium; CABG = Coronary Artery Bypass Grafting; dAPT = dual antiplatelet therapy; MI = 
Myocardial Infarction; PCI = percutaneous coronary intervention ; PFT = Platelet Function Testing ; POD 4 = 
Postoperative day 4 
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Figure 2. 
Perioperative changes in platelet function test values in response to surgery. Increases in ASPI test values in aspirin-
monotherapy group (A) and aspirin “responders” group (B) in response to surgery. Changes in ADP test values in the 
aspirin-monotherapy group (C) and aspirin “responders” group (D) in response to surgery.* Wilcoxon matched-pairs 
test. ASPI = cyclooxygenase-dependent platelet aggregation ; ADP = adenosine di-phosphate dependent plateet 
aggregation 
 
 
 
 
